(1R,2S)-2-(methylamino)-1-phenylpropan-1-ol

一般成人劑量：
肌肉或皮下注射，25-50mg，必要時重複給藥。
靜脈注射，5-25mg緩慢注射，必要時5-10分鐘再注射一次。
一般成人處方限量：每24小時可達150mg。

一般兒童劑量：
肌肉或皮下注射，每公斤體重500mcg或每平方公尺體表面積16.7mg，每4-6小時一次。

Distribution
Excreted in breast milk.

Metabolism
Small amounts are slowly metabolized in the liver.

Elimination
Renally eliminated and mostly as unchanged drug. The t ½ is approximately 3 to 6 h (dependent on urinary pH).

Onset
Immediate (IV). More than 20 min (subcutaneous). 10 to 20 min (IM). 15 to 60 min (oral).

Duration
1 h (parenteral). 3 to 5 h (oral).

Alpha-adrenergic blockers (eg, phentolamine)
Vasoconstricting and hypertensive effects are antagonized.

Diuretics
Vascular response may be decreased.

General anesthetics (eg, halothane, cyclopropane), cardiac glycosides
The potential for the myocardium to be sensitized to the effects of sympathomimetic amines is increased. Arrhythmias may result with coadministration and may respond to beta blockers.

Guanethidine
May negate antihypertensive effects.

MAOIs
Increases pressor response from vasopressors significantly; hypertensive crisis and intracranial hemorrhage are possible.

Rauwolfia alkaloids, methyldopa, furazolidone
May result in hypertension.

Tricyclic antidepressants
May potentiate pressor response.

Urinary acidifiers
May increase elimination of ephedrine.

Urinary alkalinizers
May decrease elimination of ephedrine.

Incompatibility
Ephedrine is chemically incompatible with sodium bicarbonate; avoid admixture.